Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $55 to $74.
June 04, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Crinetics Pharmaceuticals and raises the price target from $55 to $74.
The raised price target from $55 to $74 by a reputable analyst at Oppenheimer is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100